Immune Pharmaceuticals Announces the launch of REMAIN an international Overall Survival study with Ceplene and low dose Proleukin in REmission MAINtenance in Acute Myeloid Leukemia

NEW YORK Feb. 17 2017 PRNewswire Immune Pharmaceuticals Inc. Nasdaq IMNP will announce on Monday February 20th 2017 at the Acute Leukemia XVI symposium in Munich Germany that it will be launching REMAIN an international Overall Survival clinical study wit...